Retatrutide

Retatrutide is an investigational peptide engineered to activate GIP, GLP-1, and glucagon receptors. Clinical research is examining coordinated incretin and glucagon-receptor signaling.

Simultaneous agonism of GIP, GLP-1, and glucagon receptors is intended to combine incretin-mediated metabolic signaling with glucagon-receptor effects on energy expenditure and substrate metabolism.

Meaningful human investigation, including phase 2 and phase 3 clinical programs.

Level II, Meaningful human investigation

Retatrutide remains investigational. Trial findings do not establish commercial availability, safety for unsupervised use, or equivalence of independently manufactured material.

Clinical studies have reported dose-related gastrointestinal effects, appetite changes, and changes in heart rate among monitored outcomes. Long-term safety remains under investigation.

Investigational; no FDA-approved retatrutide drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.